Print This Page

Important Safety Information Full Prescribing Information


Emetogenicity Chart

Factors to consider when assessing patient risk for CINV

Emetogenicity of chemotherapy agents1

HIGH emetic risk - >90% of frequency emesis

  • AC combination defined as either doxorubicin or epirubicin with cyclophosphamide
  • Carmustine >250 mg/m2
  • Cisplatin ≥50 mg/m2
  • Cyclophosphamide >1500 mg/m2
  • Dacarbazine
  • Mechlorethamine
  • Streptozocin

MODERATE emetic risk - 30%-90% frequency of emesis

  • Aldesleukin >12-15 million IU/m2
  • Altretamine
  • Amifostine >300 mg/m2
  • Arsenic trioxide
  • Azacitidine
  • Bendamustine
  • Busulfan
  • Carboplatin
  • Carmustine ≤250 mg/m2
  • Cisplatin <50 mg/m2
  • Clofarabine
  • Cyclophosphamide ≤1500 mg/m2
  • Cytarabine >200 mg/m2
  • Dactinomycin
  • Daunorubicin
  • Doxorubicin
  • Epirubicin
  • Idarubicin
  • Ifosfamide
  • Interferon alpha ≥10 million IU/m2
  • Irinotecan
  • Melphalan
  • Methotrexate 250 mg/m2 >1000 mg/m2
  • Oxaliplatin
  • Temozolomide

Patient-related risk factors2

  • History and severity of CINV
  • History of morning sickness
  • History of motion sickness
  • Low alcohol use
  • Female sex
  • Less than 50 years of age

Indication

In adults, ALOXI® (palonosetron HCl) injection 0.25 mg is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.

Important Safety Information

  • Aloxi is contraindicated in patients known to have hypersensitivity to the drug of any of its components
  • Most commonly reported adverse reactions in chemotherapy-induced nausea and vomiting include headache (9%) and constipation (5%)

For more information about ALOXI, please see Full Prescribing Information

References
  1. Referenced and adapted with permission from The NCCN Clinical Practice Guidelines in Oncology™ Antiemesis V.1.2010. © 2010 National Comprehensive Cancer Network, Inc. All rights reserved. These Guidelines and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES™, and all other NCCN content are trademarks owned by the National Comprehensive Cancer Network, Inc.
  2. National Cancer Institute. General risk factors and etiologies. Available at: http://www.cancer.gov/cancertopics/pdq/supportivecare/nausea/HealthProfessional/page4. Accessed July 7, 2010.
Sitemap | Legal Notice and Disclaimers | Privacy

This information is intended for use by healthcare professionals in the United States only. Eisai Inc. recognizes that the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States.

ALOXI® is a registered trademark of Helsinn Healthcare SA, Switzerland, used under license.
Distributed and marketed by Eisai Inc.
© 2010 Eisai Inc.
All rights reserved. AL562B 7/10